A South Oakland biotech startup has rejected a request by a major shareholder to issue a special $1 per share dividend as the company continues a strategic review of operations in a tough environment for investment capital.
The NeuBase Therapeutics Inc. board turned down a request by Symetryx Corp., a privately owned venture capital firm based in Toronto, Canada, for a special $1 per share dividend, saying the board “does not believe that shareholder value will be enhanced” by the payout. In a prepared statement, NeuBase said it welcomed input from shareholders and will continue to seek an “open and active” dialogue with Symetryx and other shareholders.
Symetryx acquired 20% of Neubase’s outstanding stock on Wednesday, becoming the company’s largest shareholder. The company noted that NeuBase reported a cash balance of $14.7 million for the quarter ending June 30, making the company a “very attractive merger candidate.”
“We believe both rewarding shareholders with a dividend and looking for a merger candidate is a true win-win for shareholders,” Symetryx wrote in a statement. “As the largest shareholder of NeuBase, we would like to contribute to this review process and ensure that shareholder money and value is preserved.”
In August, NeuBase announced that it was licensing its gene therapy for Huntington’s disease to Helexva Inc., a Delaware corporation founded in January and managed by Robert Friedlander, chair, Department of Neurological Surgery at the University of Pittsburgh School of Medicine. Serial entrepreneur Stephan Dietrich founded NeuBase in 2009, which became publicly traded in 2019 following a reverse merger with Ohr Pharmaceuticals.
Kris B. Mamula: kmamula@post-gazette.com






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.